UK consumers reduced their purchases of food and alcohol during the holiday season, with industry experts attributing the decline to the popularity of weight loss injections.
According to data from market researcher NielsenIQ, grocery sales reached £19.6 billion in the four weeks leading up to December 27, representing a 2.5% increase from the previous year. However, sales in terms of volume saw a slight decrease of 0.2%.
Analysts suggest that the drop in food and alcohol sales is linked to the growing use of GLP-1 injections, which mimic a hormone that induces a feeling of fullness in the body. These injections, such as Mounjaro and Wegovy for weight loss and Ozempic for diabetes, have been utilized by approximately 1.6 million adults in the UK over the past year.
Experts in the retail sector have observed a noticeable impact of these injections on consumer behavior, with a shift towards consuming smaller quantities of high-calorie products like snacks and alcohol. Retailers are adapting to this trend by introducing smaller meal options, such as Co-op’s new “mini meals” range and Marks & Spencer’s “nutrient dense” offerings. Iceland has also expanded its frozen ready meal selection with 38 new products.
The influence of weight loss medications on consumer habits has not gone unnoticed by industry leaders. Greggs reported a lower growth rate in sales compared to previous years, partly attributed to the impact of weight loss injections. Chief executives of major retailers like Tesco and Sainsbury’s have acknowledged the need to closely monitor consumer trends in response to the rise in weight loss treatments.
As consumer preferences evolve towards healthier eating habits, retailers are adjusting their product offerings to cater to the demand for smaller portions and more nutritional options. The impact of weight loss medications on the retail sector is prompting businesses to rethink their strategies and product lines to align with changing consumer behaviors.
